Natalie Tafel
Physician Assistant · New York, NYNPI 1760537229
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,651 of the $76,644 with a category attached, or 60.9%. 26 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 43.2% of the total. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $353.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- Rigel Pharmaceuticals, Inc.$30K
- Servier Pharmaceuticals LLC$8K
- Amgen$2K
- Novartis$595
- Geron Corporation$513
- plus $2K from 20 others
What the payments were for
- Consulting fees$7,43310%
- Speaking & faculty fees$46,65161%
- Travel & lodging$17,23322%
- Food & beverage$5,2677%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 59 | $33,090 |
| Rigel Pharmaceuticals, Inc. | 41 | $30,209 |
| Servier Pharmaceuticals LLC | 30 | $8,138 |
| Amgen | 5 | $2,187 |
| Novartis | 26 | $595 |
| Geron Corporation | 1 | $513 |
| Sobi, Inc | 12 | $388 |
| AstraZeneca | 3 | $301 |
| Incyte Corporation | 2 | $250 |
| GSK | 4 | $192 |
| Daiichi Sankyo Inc. | 7 | $162 |
| Jazz Pharmaceuticals Inc. | 4 | $101 |
| Pfizer | 5 | $96 |
| Azurity Pharmaceuticals, Inc. | 2 | $61 |
| Astellas Pharma US Inc | 2 | $56 |
| Taiho Oncology, Inc. | 2 | $49 |
| Bristol Myers Squibb | 2 | $37 |
| Genentech USA, Inc. | 2 | $34 |
| Merck | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Sanofi | 1 | $22 |
| AbbVie | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $21 |
| CTI Biopharma Corp. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,644 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 68 | $1,165,489 |
| TibsovoIvosidenib | 26 | $860,902 |
| ScemblixAsciminib Hydrochloride | 32 | $678,115 |
| OjjaaraMomelotinib Dihydrochloride | 22 | $609,553 |
| VenclextaVenetoclax | 44 | $426,614 |
| IclusigPonatinib Hcl | 17 | $345,266 |
| InqoviDecitabine/Cedazuridine | 34 | $258,632 |
| ReblozylLuspatercept-Aamt | 21 | $205,194 |
| SprycelDasatinib | 14 | $169,090 |
| GleevecImatinib Mesylate | 18 | $168,538 |
| PegasysPeginterferon Alfa-2a | 11 | $57,772 |
| Posaconazole | 11 | $14,414 |
| Fluconazole | 14 | $1,225 |
| Hydroxyurea | 47 | $1,097 |
| ValacyclovirValacyclovir Hcl | 54 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $250 | $1,165,48968 claims |
| Servier Pharmaceuticals LLCTibsovo | $8,138 | $860,90226 claims |
| NovartisScemblix, Gleevec | $595 | $846,65450 claims |
| GSKOjjaara | $192 | $609,55322 claims |
| AbbVieVenclexta | $22 | $426,61444 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $33,090 | $345,26617 claims |
| Taiho Oncology, Inc.Inqovi | $49 | $258,63234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in New York
- Kristyl Cuenca-SiskoNew York$478K
- Cameron KiserNew York$225K
- Mervat FalahNew York$143K
- Marlene TaylorNew York$109K
- Jonathan YehNew York$57K
- Emily ElbogenNew York$49K
- Jaclyn ChurchillNew York$48K
- Russell BrandweinNew York$44K
- Michelle MelchiorreNew York$35K
- Raya GalibovNew York$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.